Coronary ischemic patients. Chronic ischemic heart disease
Conditions
Interventions
Intervention 1: Intervention group:Erythropoietin is a precursor of erythrocytes (erythrocytes) which in the intravenous form has no side effects except mild nausea and hypertension and also has a pro
Sponsors
Iran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
40 Years to 80 Years
Inclusion criteria
Inclusion criteria: Patients with ischemic coronary artery disease who are not eligible for angiographic treatment and who are candidates for surgery for coronary artery disease (CABG) 2-Patients with ischemic coronary artery disease aged 40 to 80 years
Exclusion criteria
Exclusion criteria: 1- Patients undergoing heart replacement surgery under open heart surgery 2- Anatomical heart disease undergoing open heart surgery 3- Patients with coronary artery disease who have cardiac-respiratory arrest under open heart surgery
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The presence or absence of erythropoietin in the cardioplegia solution. Timepoint: After surgery. Method of measurement: Researcher Information. | — |
Secondary
| Measure | Time frame |
|---|---|
| Total postoperative hospital stay. Timepoint: After Surgery. Method of measurement: Based on the case.;Duration of ICU admission. Timepoint: Operation time until leaving ICU. Method of measurement: Based on the case.;The dose of inotropes required after surgery. Timepoint: After Surgery. Method of measurement: Based on the case. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactBehdad Maadani
Iran University of Medical Sciences
Outcome results
None listed